Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 7, Pages 3940-3955
Publisher
American Chemical Society (ACS)
Online
2021-03-30
DOI
10.1021/acs.jmedchem.0c02085
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitors of BRAF dimers using an allosteric site
- (2020) Xiomaris M. Cotto-Rios et al. Nature Communications
- Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic
- (2019) Savithri Ramurthy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting ERK beyond the boundaries of the kinase active site in melanoma
- (2019) Rachel M. Sammons et al. MOLECULAR CARCINOGENESIS
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Insights of BRAF Inhibitors in Cancer
- (2018) Bogos Agianian et al. JOURNAL OF MEDICINAL CHEMISTRY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
- (2018) Jimin Yuan et al. ONCOGENE
- Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
- (2018) Ivana Yen et al. CANCER CELL
- Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
- (2017) Gisele A. Nishiguchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Current Development Status of MEK Inhibitors
- (2017) et al. MOLECULES
- RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
- (2017) S-H Chen et al. ONCOGENE
- An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
- (2016) Zoi Karoulia et al. CANCER CELL
- Kinase hinge binding scaffolds and their hydrogen bond patterns
- (2015) Li Xing et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
- (2015) James R. Henry et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors
- (2015) Rohit Arora et al. JOURNAL OF MEDICINAL CHEMISTRY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suzuki-Miyaura Cross-Coupling of Unprotected, Nitrogen-Rich Heterocycles: Substrate Scope and Mechanistic Investigation
- (2013) M. Alexander Düfert et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors
- (2012) Steve Wenglowsky et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties
- (2012) Simon Mathieu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors
- (2012) Emily J. Hanan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
- (2012) Kenneth D. Rice et al. ACS Medicinal Chemistry Letters
- Overview of theCCP4 suite and current developments
- (2011) Martyn D. Winn et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- (2011) K. P. Hoeflich et al. CANCER RESEARCH
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
- (2011) Hiroyuki Abe et al. ACS Medicinal Chemistry Letters
- New Insight Puts CRAF in Sight as a Therapeutic Target: Figure 1.
- (2011) Ana Paula Rebocho et al. Cancer Discovery
- Integration, scaling, space-group assignment and post-refinement
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- A New Palladium Precatalyst Allows for the Fast Suzuki−Miyaura Coupling Reactions of Unstable Polyfluorophenyl and 2-Heteroaryl Boronic Acids
- (2010) Tom Kinzel et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Pd-catalyzed amidation of aryl(Het) halides with tert-butyl carbamate
- (2010) Lijin Qin et al. TETRAHEDRON LETTERS
- Entry into a new class of protein kinase inhibitors by pseudo ring design
- (2008) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides
- (2008) Brett P. Fors et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Facile Synthesis of N-Carbamoylamino Acids
- (2008) Sergey Ryabukhin et al. SYNLETT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation